MX2012014291A - Agentes anti-inflamatorios. - Google Patents

Agentes anti-inflamatorios.

Info

Publication number
MX2012014291A
MX2012014291A MX2012014291A MX2012014291A MX2012014291A MX 2012014291 A MX2012014291 A MX 2012014291A MX 2012014291 A MX2012014291 A MX 2012014291A MX 2012014291 A MX2012014291 A MX 2012014291A MX 2012014291 A MX2012014291 A MX 2012014291A
Authority
MX
Mexico
Prior art keywords
compounds
inflammatory agents
formulae
aromatic
preventing
Prior art date
Application number
MX2012014291A
Other languages
English (en)
Inventor
David John Grainger
David John Fox
Original Assignee
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012014291(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cambridge Entpr Ltd filed Critical Cambridge Entpr Ltd
Publication of MX2012014291A publication Critical patent/MX2012014291A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Se describen aquí los métodos para prevenir o tratar enfermedades inflamatorias usando análogos de sulfanamida de compuestos 3-aminolactama, cada uno con "grupos de cola" aromáticos. Los compuestos definidos por las fórmulas (I) y (I'), y los usos médicos de los compuestos, se describen en la presente memoria.
MX2012014291A 2010-06-08 2011-06-08 Agentes anti-inflamatorios. MX2012014291A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1009603.0A GB201009603D0 (en) 2010-06-08 2010-06-08 Anti-inflammatory agent
PCT/GB2011/000862 WO2011154695A1 (en) 2010-06-08 2011-06-08 Anti-inflammatory agents

Publications (1)

Publication Number Publication Date
MX2012014291A true MX2012014291A (es) 2013-05-01

Family

ID=42471347

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012014290A MX2012014290A (es) 2010-06-08 2011-06-08 Agentes anti-inflamatorios.
MX2012014291A MX2012014291A (es) 2010-06-08 2011-06-08 Agentes anti-inflamatorios.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012014290A MX2012014290A (es) 2010-06-08 2011-06-08 Agentes anti-inflamatorios.

Country Status (21)

Country Link
US (2) US20130203734A1 (es)
EP (2) EP2580196A1 (es)
JP (2) JP2013528201A (es)
KR (2) KR20130115082A (es)
CN (2) CN103119021A (es)
AP (2) AP2012006560A0 (es)
AU (1) AU2011263531A1 (es)
BR (2) BR112012031136A2 (es)
CA (2) CA2798129A1 (es)
CL (1) CL2012003460A1 (es)
CO (2) CO6670569A2 (es)
GB (1) GB201009603D0 (es)
IL (2) IL222798A0 (es)
MA (2) MA34369B1 (es)
MX (2) MX2012014290A (es)
PE (2) PE20131046A1 (es)
PH (2) PH12012502167A1 (es)
SG (2) SG185129A1 (es)
TN (2) TN2012000521A1 (es)
WO (2) WO2011154695A1 (es)
ZA (2) ZA201208367B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4788C1 (ro) * 2017-09-07 2022-09-30 Ооо "Валента-Интеллект" Utilizarea derivatului de glutarimidă pentru tratarea afecţiunilor, legate de activitatea aberantă a citokinelor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3054738B2 (ja) * 1988-07-22 2000-06-19 武田薬品工業株式会社 チアゾロ［５，４―ｂ］アゼピン誘導体
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
IT1247698B (it) 1990-06-21 1994-12-30 Sigma Tau Ind Farmaceuti 1-alchil-3-(acilammino)-e-caprolattami quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
DE4117507A1 (de) * 1991-05-24 1992-11-26 Schering Ag Verfahren zur herstellung von n(pfeil hoch)6(pfeil hoch)-substituierten lysin-derivaten
JP3206042B2 (ja) 1991-10-31 2001-09-04 ミノルタ株式会社 新規トリアミノ化合物を用いた電荷輸送材料、このトリアミノ化合物を含有する感光体およびエレクトロルミネセンス素子
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
AU2610000A (en) 1999-01-12 2000-08-01 Cambridge University Technical Services Limited Compounds and methods to inhibit or augment an inflammatory response
WO2004033455A2 (en) 2002-10-08 2004-04-22 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
KR101109296B1 (ko) * 2003-03-24 2012-02-08 액시킨 파마수티컬스 인코포레이티드 천식 및 다른 염증성 또는 면역성 이상들의 치료용ｃｃｒ３ 길항 활성을 갖는 2-페녹시- 및2-페닐설폰아마이드 유도체
JP2007512242A (ja) 2003-10-29 2007-05-17 イーラン ファーマスーティカルズ、インコーポレイテッド Ｎ−置換ベンゼンスルホンアミド
KR101228268B1 (ko) * 2003-12-01 2013-01-31 캠브리지 엔터프라이즈 리미티드 항-염증제
RU2378258C2 (ru) 2004-07-13 2010-01-10 Ф. Хоффманн-Ля Рош Аг Производные сульфонамида
GB2418425B (en) 2004-08-11 2008-09-03 Univ Cambridge Tech Anti-inflammatory agents
GB2418426A (en) 2004-08-18 2006-03-29 Univ Cambridge Tech Alpha-(acylamino)-bicyclolactam derivatives for treatment of inflammatory disorders
GB2423085C (en) 2005-02-11 2011-11-09 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
WO2006134384A1 (en) * 2005-06-15 2006-12-21 Cambridge Enterprise Limited Anti-inflammatory agents
GB0512238D0 (en) * 2005-06-15 2005-07-27 Univ Cambridge Tech Anti-inflammatory agents
JP4885958B2 (ja) 2005-08-12 2012-02-29 エフ．ホフマン−ラ ロシュ アーゲー フルオロ置換２−オキソアゼパン誘導体
BRPI0616575A2 (pt) 2005-09-27 2011-06-21 Irm Llc compostos e composições contendo diarilamina, seu uso como moduladores de receptores de c-kit bem como método para sua produção
WO2009017620A1 (en) 2007-07-26 2009-02-05 Ipsen Pharma S.A.S. Chemokine analogs
GB2452696B (en) 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions

Also Published As

Publication number Publication date
JP2013531647A (ja) 2013-08-08
IL222866A0 (en) 2012-12-31
MA34370B1 (fr) 2013-07-03
CA2798129A1 (en) 2011-12-15
KR20130115082A (ko) 2013-10-21
CO6670553A2 (es) 2013-05-15
US20130172318A1 (en) 2013-07-04
PE20130772A1 (es) 2013-07-03
PH12012502167A1 (en) 2013-01-07
AU2011263531A1 (en) 2012-11-22
CA2798213A1 (en) 2011-12-15
SG185129A1 (en) 2012-12-28
MA34369B1 (fr) 2013-07-03
SG185130A1 (en) 2012-12-28
US20130203734A1 (en) 2013-08-08
BR112012031136A2 (pt) 2017-08-08
PE20131046A1 (es) 2013-09-23
AP2012006560A0 (en) 2012-12-31
PH12012502169A1 (en) 2013-01-07
ZA201208406B (en) 2013-07-31
ZA201208367B (en) 2013-10-30
WO2011154695A1 (en) 2011-12-15
KR20130086952A (ko) 2013-08-05
TN2012000521A1 (en) 2014-04-01
EP2580197A1 (en) 2013-04-17
AP2012006559A0 (en) 2012-12-31
JP2013528201A (ja) 2013-07-08
CO6670569A2 (es) 2013-05-15
CL2012003460A1 (es) 2013-08-16
WO2011154696A1 (en) 2011-12-15
CN103080090A (zh) 2013-05-01
CN103119021A (zh) 2013-05-22
MX2012014290A (es) 2013-05-01
GB201009603D0 (en) 2010-07-21
TN2012000525A1 (en) 2014-04-01
IL222798A0 (en) 2012-12-31
BR112012030816A2 (pt) 2016-11-01
EP2580196A1 (en) 2013-04-17

Similar Documents

Publication Publication Date Title
EA201201648A1 (ru) Стимуляторы sgc
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
MA32811B1 (fr) Nouveaux composés
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
CO7101245A2 (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido
MX354021B (es) Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona.
EA201390885A1 (ru) Азаиндолы в качестве противовирусных агентов против респираторного синцитиального вируса
PH12012502369A1 (en) Purinone derivative
NZ603151A (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
UY31228A1 (es) Ariloxazoles sustituidos y su uso
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
MX356210B (es) Formulaciones de polimero acrilico.
PH12013501882A1 (en) Antimicrobial agents
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
MX340574B (es) Imidazo pirazinas.
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
CR20130106A (es) Nuevos moduladores de trpv3
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
EA201390925A1 (ru) Производные санглиферина и способы их получения